- Home
- LZB vs MYGN Comparison
LZB vs MYGN Comparison
Compare LZB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- MYGN
- Stock Information
- Founded
- LZB 1927
- MYGN 1991
- Country
- LZB United States
- MYGN United States
- Employees
- LZB N/A
- MYGN N/A
- Industry
- LZB Home Furnishings
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LZB Consumer Discretionary
- MYGN Health Care
- Exchange
- LZB Nasdaq
- MYGN Nasdaq
- Market Cap
- LZB 1.8B
- MYGN 2.0B
- IPO Year
- LZB N/A
- MYGN 1995
- Fundamental
- Price
- LZB $44.86
- MYGN $12.39
- Analyst Decision
- LZB Hold
- MYGN Hold
- Analyst Count
- LZB 1
- MYGN 12
- Target Price
- LZB N/A
- MYGN $23.92
- AVG Volume (30 Days)
- LZB 372.6K
- MYGN 1.0M
- Earning Date
- LZB 02-18-2025
- MYGN 02-25-2025
- Dividend Yield
- LZB 1.94%
- MYGN N/A
- EPS Growth
- LZB 4.44
- MYGN N/A
- EPS
- LZB 2.90
- MYGN N/A
- Revenue
- LZB $2,070,500,000.00
- MYGN $823,600,000.00
- Revenue This Year
- LZB $3.32
- MYGN $13.82
- Revenue Next Year
- LZB $3.97
- MYGN $4.59
- P/E Ratio
- LZB $15.59
- MYGN N/A
- Revenue Growth
- LZB N/A
- MYGN 12.15
- 52 Week Low
- LZB $32.00
- MYGN $12.17
- 52 Week High
- LZB $46.47
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- LZB 58.47
- MYGN 29.80
- Support Level
- LZB $44.33
- MYGN $12.17
- Resistance Level
- LZB $44.52
- MYGN $15.08
- Average True Range (ATR)
- LZB 1.06
- MYGN 0.79
- MACD
- LZB 0.14
- MYGN -0.01
- Stochastic Oscillator
- LZB 81.40
- MYGN 7.56
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.